Enbrel's phase III reinforces prospects in RA.
Brower
V
V
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D017326:Clinical Trials, Phase III as Topic; D003094:Collagen / Q000627:therapeutic use*; D006801:Humans; D016753:Interleukin-10 / Q000037:antagonists & inhibitors; D015847:Interleukin-4 / Q000037:antagonists & inhibitors; D010919:Placebos; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D010919:Placebos; D018124:Receptors, Tumor Necrosis Factor; D011994:Recombinant Proteins; D016753:Interleukin-10; D015847:Interleukin-4; D003094:Collagen